Tarsus Pharmaceuticals, Inc. TARS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s total current liabilities?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total current liabilities of $143.51M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s total current liabilities increased by 66.3% year-over-year, from $86.31M to $143.51M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s total current liabilities has grown at a 90.7% compound annual growth rate (CAGR), from $5.39M to $135.7M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.